Tirzepatide is a novel dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has gained significant attention for its role in managing type 2 diabetes and promoting weight loss. Its unique dual action offers enhanced glycemic control and metabolic benefits beyond existing GLP-1 receptor agonists.
Tirzepatide was developed as a next-generation therapy for diabetes and obesity, receiving FDA approval in 2022 for the treatment of type 2 diabetes. Clinical trials have demonstrated its exceptional efficacy in improving glycemic control and inducing significant weight loss, sparking interest in its broader therapeutic applications.
SKU: MAF/TIRZ/20.60.100/SV/KIT
